Cholangiocarcinoma in the Era of Immunotherapy.
adoptive cell therapy
cancer vaccines
checkpoint inhibitors
cholangiocarcinoma
immunotherapy
Journal
Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355
Informations de publication
Date de publication:
05 Jun 2023
05 Jun 2023
Historique:
received:
25
04
2023
revised:
27
05
2023
accepted:
03
06
2023
medline:
28
6
2023
pubmed:
28
6
2023
entrez:
28
6
2023
Statut:
epublish
Résumé
Cholangiocarcinoma (CCA) is a rare malignancy of the gastrointestinal tract, with aggressive behavior, and portends a poor prognosis. Traditionally, it is classified according to its site of involvement as intrahepatic, perihilar, and distal cholangiocarcinoma. A host of genetic and epigenetic factors have been involved in its pathogenesis. Chemotherapy has remained the standard first-line treatment over the last decade, with a disappointing median overall survival of 11 months for locally advanced and metastatic CCA. The advent of immunotherapy has revolutionized the treatment of many pancreaticobiliary malignancies, offering durable responses with a safe therapeutic profile. To date, there have been no significant advances in the management of CCA. Novel immunotherapeutic methods, such as cancer vaccines, adoptive cell therapy, and combinations of immune checkpoint inhibitors with other agents, are currently under investigation and may improve prognosis with overall survival. Efforts to find robust biomarkers for response to treatment along with multiple clinical trials are also ongoing in this regard. In this review, we present an overview of the current advances and the future perspectives of immunotherapy in the management of CCA.
Identifiants
pubmed: 37376451
pii: vaccines11061062
doi: 10.3390/vaccines11061062
pmc: PMC10301507
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Mol Cancer. 2021 Mar 8;20(1):50
pubmed: 33685460
J Exp Clin Cancer Res. 2022 Apr 7;41(1):127
pubmed: 35392957
J Hepatol. 2021 May;74(5):1145-1154
pubmed: 33276030
J Immunother Cancer. 2020 May;8(1):
pubmed: 32461347
Int J Cancer. 2021 Dec 1;149(11):1944-1954
pubmed: 34309846
Liver Cancer. 2021 Sep 21;10(6):545-560
pubmed: 34950178
Oncologist. 2022 Mar 11;27(3):e273-e285
pubmed: 35274717
J Transl Med. 2014 Mar 07;12:61
pubmed: 24606884
Cancers (Basel). 2023 Apr 20;15(8):
pubmed: 37190307
Cancers (Basel). 2022 Mar 29;14(7):
pubmed: 35406520
Int J Cancer. 2020 Oct 15;147(8):2190-2198
pubmed: 32359091
Cancer Med. 2022 Jul;11(13):2550-2560
pubmed: 35611499
Clin Cancer Res. 2018 Mar 15;24(6):1277-1286
pubmed: 29138340
Oncogene. 2016 Jun 16;35(24):3209-16
pubmed: 26477306
Hepatology. 2019 May;69(5):2048-2060
pubmed: 30578687
Signal Transduct Target Ther. 2020 Oct 7;5(1):230
pubmed: 33028805
Molecules. 2019 Mar 26;24(6):
pubmed: 30917623
Cancers (Basel). 2020 Apr 03;12(4):
pubmed: 32260179
JAMA Oncol. 2020 Sep 1;6(9):1405-1409
pubmed: 32729929
Int J Mol Sci. 2022 Nov 12;23(22):
pubmed: 36430440
Nat Rev Clin Oncol. 2018 Feb;15(2):95-111
pubmed: 28994423
Cancer Res. 2016 Mar 15;76(6):1578-90
pubmed: 26979791
J Gastrointest Surg. 2013 Sep;17(9):1609-17
pubmed: 23877328
Sci Rep. 2021 Mar 18;11(1):6276
pubmed: 33737613
Int Immunopharmacol. 2020 Jan;78:106006
pubmed: 31780372
Drugs. 2018 Feb;78(2):155-162
pubmed: 29350327
Br J Cancer. 2022 Apr;126(7):1010-1017
pubmed: 34903842
J Immunother Cancer. 2020 Jun;8(1):
pubmed: 32487569
Br J Cancer. 2010 Aug 10;103(4):469-74
pubmed: 20628385
J Immunother Cancer. 2020 Apr;8(1):
pubmed: 32317293
J Clin Oncol. 2020 Jan 1;38(1):1-10
pubmed: 31682550
JAMA Oncol. 2020 Jun 1;6(6):888-894
pubmed: 32352498
J Gastrointest Cancer. 2021 Mar;52(1):1-10
pubmed: 32700185
Clin Cancer Res. 2017 Sep 15;23(18):5394-5405
pubmed: 28916617
Front Immunol. 2018 Oct 01;9:2265
pubmed: 30327656
Gut. 2023 Apr;72(4):736-748
pubmed: 35584893
Life (Basel). 2022 Apr 30;12(5):
pubmed: 35629333
Ann Hepatol. 2022 Sep-Oct;27(5):100737
pubmed: 35809836
Cancer. 2022 Oct 1;128(19):3523-3530
pubmed: 35895381
Cancers (Basel). 2022 May 26;14(11):
pubmed: 35681621
Protein Cell. 2018 Oct;9(10):838-847
pubmed: 28710747
Aliment Pharmacol Ther. 2021 Feb;53(3):374-382
pubmed: 33314269
Int J Mol Sci. 2022 Jan 13;23(2):
pubmed: 35055006
Vaccines (Basel). 2020 Nov 24;8(4):
pubmed: 33255375
Cancers (Basel). 2020 Dec 16;12(12):
pubmed: 33339274
Signal Transduct Target Ther. 2023 Mar 17;8(1):106
pubmed: 36928584
Front Oncol. 2021 May 20;11:668731
pubmed: 34094963
Oncoimmunology. 2020 Jun 26;9(1):1781333
pubmed: 32923143
J Hepatobiliary Pancreat Sci. 2014 Jun;21(6):380-7
pubmed: 24532422
Hepatology. 2020 Sep;72(3):965-981
pubmed: 31875970
Anticancer Res. 2012 Jun;32(6):2249-56
pubmed: 22641659
World J Gastroenterol. 2019 Aug 7;25(29):3941-3955
pubmed: 31413529
J Hepatol. 2020 Jan;72(1):95-103
pubmed: 31536748
J Immunother. 2011 Jan;34(1):92-9
pubmed: 21150717
Aliment Pharmacol Ther. 2021 May;53(9):977-984
pubmed: 33721336
Front Oncol. 2021 Mar 03;11:657868
pubmed: 33763382
J Gastroenterol Hepatol. 2015 Nov;30(11):1643-50
pubmed: 25974743
Nat Rev Cancer. 2019 Mar;19(3):133-150
pubmed: 30755690
Front Oncol. 2021 Jun 17;11:648068
pubmed: 34221968
EBioMedicine. 2021 May;67:103375
pubmed: 33993051
N Engl J Med. 2010 Apr 8;362(14):1273-81
pubmed: 20375404
Nat Rev Gastroenterol Hepatol. 2023 Jun;20(6):349-365
pubmed: 36697706
Adv Ther. 2021 Jul;38(7):3674-3693
pubmed: 34105088
Trends Immunol. 2015 Apr;36(4):250-6
pubmed: 25758021
J Immunother Cancer. 2020 Nov;8(2):
pubmed: 33172881
Lancet Gastroenterol Hepatol. 2019 Aug;4(8):611-621
pubmed: 31109808